MedTrace Logo

Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients

NCT03321188 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-02-06

No results posted yet for this study

Summary

This study will evaluate the use of Heated Intraperitoneal Chemotherapy (HIPEC) for primary treatment of ovarian cancer at the time of surgical debulking, to assess if intravenous (IV) chemotherapy can be started within 42 days of HIPEC and cytoreduction. All patients will receive cytoreductive surgery followed by a one-time closed HIPEC with cisplatin at 41-43 degrees Celsius for 90 minutes in the operating room. This is followed by 6 cycles of intravenous carboplatin and paclitaxel on an outpatient basis.

Conditions

Interventions

PROCEDURE

HIPEC

HIPEC with cisplatin

DRUG

Carboplatin

Adjuvant IV chemotherapy

DRUG

Paclitaxel

Adjuvant IV chemotherapy

Sponsors & Collaborators

  • University of Kansas Medical Center

    collaborator OTHER

  • Andrea Jewell

    lead OTHER

Principal Investigators

  • Andrea Jewell, MD · The University of Kansas - Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-15
Primary Completion
2023-12-15
Completion
2024-12-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03321188 on ClinicalTrials.gov